Objective: The objective of this scoping review is to understand the extent and type of evidence in relation to bacterial diagnostic approaches in paediatric cancer patients with febrile neutropenia (FN), with the goals of highlighting the best practice approach to conventional microbiological testing used in current clinical practice and explore the role of emerging technologies as potential diagnostic tools. Introduction: FN is a common complication for children undergoing chemotherapy for cancer, with bacterial bloodstream infection responsible for the majority of serious adverse events. Current diagnostic approaches have limited sensitivity and long turnaround times. Improved diagnostics are required to strengthen clinical decision rules and support the safer use of reduced-intensity management pathways. Eligibility Criteria: Children up to their 18th birthday with a diagnosis of cancer will be included, looking at bacterial diagnostic methods used in the evaluation of FN. Studies conducted across all healthcare settings will be considered. Studies focusing exclusively on viral or fungal diagnostics will be excluded, as will those not involving human participants. Methods: The review will be conducted in accordance with Joanna Briggs Institute and PRISMA-Scoping Review methodology. A comprehensive search of MEDLINE, Embase, Web of Science Core Collection and grey literature will be conducted to identify published and unpublished studies from 2011 onwards, with no language restrictions. Primary research studies of any design will be included, however case reports with fewer than 10 participants will be excluded. Two independent reviewers will screen studies and extract data. Any discrepancies will be resolved by consensus, involving a third reviewer if necessary. Findings will be synthesised and presented using tables and figures, accompanied by a narrative synthesis to address the research question.
12 June 2026 in Archives of Disease in Childhood - Education & Practice Edition
This article describes a case of warm autoimmune haemolytic anaemia (w-AIHA) in a 16-month-old refractory to first-line treatment. W-AIHA typically responds to systemic corticosteroids. Here, management proved challenging with re-emergence of haemolysis during initial steroid course. Rituximab offered a turning point, demonstrating the utility of targeted anti-CD20 antibody therapy in achieving a sustained haematological response. The patient’s clinical course was not without further complications potentially attributable to treatments administered. This paper reviews the management of w-AIHA, beyond steroid therapy, with an additional focus on supportive care measures.
29 September 2026 in Archives of Disease in Childhood
Introduction: Febrile neutropenia (FN) is a common complication of cancer treatment and carries a risk of bacterial bloodstream infection. Current diagnostic approaches have limitations, underscoring the need for improved methods. This review maps evidence on diagnostics for bacteraemia in paediatric FN, focusing on peripheral blood cultures (BCs) in children with central venous catheters, repeat BC strategies and emerging molecular diagnostics and biomarkers. Methods: A scoping review was conducted in accordance with Joanna Briggs Institute methodology and reported using the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) checklist. MEDLINE, Embase and Web of Science were searched for primary research published since 2011 evaluating diagnostic techniques for bacteraemia in children with cancer and FN. Study selection was performed independently by two reviewers. Data on study characteristics, diagnostic methods and performance were extracted. Results: Of 1641 records, 33 studies (8993 FN episodes) were included: biomarker assays (n=20), BC (n=7) and molecular diagnostics (n=6). Evidence for routine peripheral BC was limited and conflicting. A temporal decline in BC diagnostic yield was observed, associated with increasing contamination. Molecular diagnostics consistently detected more pathogens than conventional culture, although evidence of clinical benefit remains limited. No biomarker demonstrated sufficient accuracy for standalone use. Methodological heterogeneity limited comparative analysis. Conclusion: BCs remain the diagnostic gold standard for bacteraemia in paediatric FN. Repeated BCs beyond 72 hours are unlikely to benefit clinically stable patients. Molecular diagnostics and biomarkers are promising adjuncts but require further evaluation through standardised prospective multicentre studies. Integrating pathogen detection with host response biomarkers should be considered to improve diagnostic accuracy.